WGS GeneDx Holdings Corp.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Provider of clinical exome and genome sequencing diagnostics powered by proprietary GeneDx Infinity™ rare disease dataset
• • New emphasis on rapid and ultraRapid genomes, medium/long-read sequencing, and multimodal genomic analysis expansion in 2025
• • Strategic shift: Accelerating industry leadership through integration of AI-powered variant interpretation and launching global market expansion with Fabric Genomics acquisition
• • Quantitative metric: GeneDx Infinity™ dataset grew 30% in 2025, surpassing prior 24 years combined, includes 2.5M tests and 50% non-European genetic diversity
• • Noteworthy fact: Leveraged AI (Multiscore) and cloud-based platforms to improve interpretation speed and scalability while lowering sequencing costs

Risk Factors

• • Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025
• • Macroeconomic risk: reliance on reimbursement approvals from commercial and Medicaid payors, with 18% average reimbursement rate increase in 2025 impacting revenue
• • Operational risk: dependency on third-party suppliers for diagnostic test components and data storage, affecting cost and service delivery efficiency
• • Competitive risk: integration risk from Fabric Genomics acquisition to expand AI-enabled genome interpretation amid rapid technology evolution and competitors
• • Financial risk: $57.2M non-cancellable operating leases and $29.2M finance leases creating fixed cash obligations impacting liquidity management

Management Discussion & Analysis

• • Revenue and profitability details not provided in the excerpt
• • No segment performance data disclosed
• • No cash flow, capital allocation, or dividend information available
• • Forward-looking statements noted, but no specific management guidance or risk details given

What are the latest WGS SEC filings in 2026?

GeneDx Holdings Corp. (WGS) has filed a 10-K annual report on February 23, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did WGS file its most recent 10-K annual report?

GeneDx Holdings Corp. (WGS) filed its most recent 10-K annual report on February 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view WGS 10-Q quarterly reports?

GeneDx Holdings Corp. (WGS)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every WGS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has WGS filed recently?

GeneDx Holdings Corp. (WGS)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find WGS insider trading activity (Form 4)?

SignalX aggregates every WGS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does WGS file with the SEC?

GeneDx Holdings Corp. (WGS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new WGS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for GeneDx Holdings Corp. (WGS).

What is WGS's SEC CIK number?

GeneDx Holdings Corp. (WGS)'s SEC CIK (Central Index Key) number is 1818331. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1818331 to look up all WGS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find WGS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from GeneDx Holdings Corp. (WGS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.